[1] [1] Pimpinelli M, Makar M, Kahaleh M. Endoscopic management of benign and malignant hilar stricture[J]. Dig Endosc, 2023, 35(4): 443-452.

[2] [2] Elmunzer BJ, Maranki JL, Gmez V, et al. ACG clinical guideline: diagnosis and management of biliary strictures[J]. Am J Gastroenterol, 2023, 118(3): 405-426.

[3] [3] Dyson JK, Beuers U, Jones DEJ, et al. Primary sclerosing cholangitis[J]. Lancet, 2018, 391(10139): 2547-2559.

[4] [4] Luo G, Jin K, Deng S, et al. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(2): 188409.

[5] [5] Liu W, Liu Q, Wang W, et al. Differential diagnostic roles of the serum CA19-9, total bilirubin(TBIL)and the ratio of CA19-9 to TBIL for benign and malignant[J]. J Cancer, 2018, 9(10): 1804-1812.

[6] [6] La Greca G, Sofia M, Lombardo R, et al. Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein[J]. World J Gastroenterol, 2012, 18(31): 4150-4155.

[10] [10] Garcea G, Ngu W, Neal CP, et al. Bilirubin levels predict malignancy in patients with obstructive jaundice[J]. HPB(Oxford), 2011, 13(6): 426-430.

[11] [11] Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors[J]. World J Oncol, 2019, 10(1): 10-27.

[12] [12] Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(7): 493-502.

[13] [13] Rustagi T, Dasanu CA. Risk factors for gallbladder cancer and cholangiocarcinoma: similarities, differences and updates[J]. J Cancer Res The, 2012, 43(2): 137-147.

[14] [14] Sun Z, Feng Y, Liu H, et al. Analysis of treatment methods and prognostic factors in 354 cases of hilar cholangiocarcinoma: A cohort study[J]. J Cancer Res Ther, 2020, 16(2): 230-237.

[16] [16] Kim MS, Jeon TJ, Park JY, et al. Clinical interpretation of elevated CA19-9 levels in obstructive jaundice following benign and malignant pancreatobiliary disease[J]. Korean J Gastroenterol, 2017, 70(2): 96-102.

[17] [17] Marrelli D, Caruso S, Pedrazzani C, et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions[J]. Am J Surg, 2009, 198(3): 333-339.

[19] [19] Lin ZQ, Ma C, Cao WZ, et al. Prognostic significance of NLR, PLR, LMR and tumor infiltrating T lymphocytes in patients undergoing surgical resection for hilar cholangiocarcinoma[J]. Front Oncol, 2022, 12: 908907.